Edition:
International

Biotechnology & Medical Research

Page 1

Alterity Therapeutics Gets Positive Guidance For ATH434 Phase 2 Clinical Trial

8:56pm EDT

June 23 (Reuters) - Alterity Therapeutics Ltd ::GETS POSITIVE GUIDANCE FROM EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR ATH434 PHASE 2 CLINICAL TRIAL.

Neuroscientific Biopharmaceuticals Says Paul Rennie Appointed Non-Executive Chairman

Monday, 21 Jun 2021 06:18pm EDT

June 22 (Reuters) - NeuroScientific Biopharmaceuticals Ltd ::NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - APPOINTMENT OF NON-EXECUTIVE CHAIRMAN-NSB.AX.NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD SAYS PAUL RENNIE NON-EXECUTIVE CHAIRMAN.NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - PAUL RENNIE REPLACING INTERIM CHAIRMAN ANTON UVAROV.

Lonza Collaborates With Selectimmune To Develop Immunotherapeutic Drug Candidate

Monday, 21 Jun 2021 09:06am EDT

June 21 (Reuters) - Lonza Group AG ::SELECTIMMUNE COLLABORATES WITH LONZA TO DEVELOP AN IMMUNOTHERAPEUTIC DRUG CANDIDATE.THE AGREEMENT PROVIDES ACCESS TO VECTOR CONSTRUCTION AND NON-GMP EXPRESSION OF A NOVEL IMMUNOTHERAPY PROTEIN DRUG CANDIDATE.Further company coverage: . (Berlin Speed Desk). ((frankfurt.newsroom@thomsonreuters.com;)).

Capricor Therapeutics Says On June 21, Co Filed New Prospectus Supplement With U.S. SEC To Offer And Sale Of Shares Of Common Stock Of Up To $75 Million

Monday, 21 Jun 2021 08:35am EDT

June 21 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS SAYS ON JUNE 21, CO FILED NEW PROSPECTUS SUPPLEMENT WITH U.S. SEC TO OFFER AND SALE OF SHARES OF COMMON STOCK OF UP TO $75 MILLION.

Enochian Biosciences Announces Acquisition Of Exclusive License For Potential Pan-Coronavirus And Pan-Influenza Inhaled Treatment And Prevention Technology

Monday, 21 Jun 2021 07:00am EDT

June 21 (Reuters) - Enochian Biosciences Inc ::ENOCHIAN BIOSCIENCES ANNOUNCES ACQUISITION OF EXCLUSIVE LICENSE FOR POTENTIAL PAN-CORONAVIRUS AND PAN-INFLUENZA INHALED TREATMENT AND PREVENTION TECHNOLOGY.ENOCHIAN BIOSCIENCES INC - REQUEST FOR A PRE-INVESTIGATOR NEW DRUG MEETING FOR COVID-19 TREATMENT WILL BE SUBMITTED TO FDA IN NEAR TERM.

Anavex Life Sciences Announces Anavex2-73 (Blarcamesine) Biomarker Correlated With Efficacy Endpoints In Placebo-Controlled U.S. Phase 2 Clinical Trial For The Treatment Of Adult Patients With R

Monday, 21 Jun 2021 07:00am EDT

June 21 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES ANNOUNCES ANAVEX®2-73 (BLARCAMESINE) BIOMARKER CORRELATED WITH EFFICACY ENDPOINTS IN PLACEBO-CONTROLLED U.S. PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF ADULT PATIENTS WITH RETT SYNDROME.ANAVEX LIFE SCIENCES CORP - OUTCOME OF TRIAL IS "VERY PROMISING" IN TERMS OF BOTH SAFETY AND CLINICAL IMPROVEMENT.ANAVEX LIFE SCIENCES CORP - ANAVEX IS PLANNING TO MEET WITH FDA TO DISCUSS APPROVAL PATHWAY.

Medicinova Announces Positive Results From Phase 2 Trial Of Mn-166 (Ibudilast) In Alcohol Use Disorder Published In Nature’S Translational Psychiatry Journal

Monday, 21 Jun 2021 06:30am EDT

June 21 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MN-166 (IBUDILAST) IN ALCOHOL USE DISORDER PUBLISHED IN NATURE’S TRANSLATIONAL PSYCHIATRY JOURNAL.MEDICINOVA INC - KEY RESULTS REPORTED IN PUBLICATION INCLUDE IBUDILAST DID NOT HAVE A SIGNIFICANT EFFECT ON NEGATIVE MOOD.MEDICINOVA INC - KEY RESULTS REPORTED IN PUBLICATION INCLUDE IBUDILAST, RELATIVE TO PLACEBO, REDUCED ODDS OF HEAVY DRINKING ACROSS TIME BY 45%.

Albireo Announces Expanded Phase 3 Data On Bylvay(Odevixibat) And A3907 At Upcoming Easl International Liver Congress

Monday, 21 Jun 2021 06:00am EDT

June 21 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES EXPANDED PHASE 3 DATA ON BYLVAY™ (ODEVIXIBAT) AND A3907 AT UPCOMING EASL INTERNATIONAL LIVER CONGRESS.ALBIREO PHARMA INC - BYLVAY DEMONSTRATES RAPID REDUCTIONS IN SERUM BILE ACIDS AND LONG-TERM IMPROVEMENTS IN GROWTH, SLEEP, AND HEPATIC PARAMETERS.ALBIREO PHARMA INC - BYLVAY PATIENT RESPONDER DATA SHOW SUSTAINED IMPROVEMENTS IN CHOLESTASIS MARKERS VERSUS. NON-RESPONDERS.

CytoTools Reports Treatment Numbers In India Slightly Above Previous Quarter

Monday, 21 Jun 2021 03:30am EDT

June 21 (Reuters) - CYTOTOOLS AG ::TREATMENT NUMBERS IN INDIA SLIGHTLY ABOVE PREVIOUS QUARTER DESPITE SIGNIFICANT PANDEMIC IMPACT.STILL EXPECTS TO BE ABLE TO REPORT INTERIM RESULTS OF STUDY AT END OF 2021 AND THEN TO SUCCESSFULLY COMPLETE PHASE III BY END OF 2022.DESPITE DELAYS DUE TO PROGRESS OF COVID-19 IN EUROPE, MANAGEMENT BOARD ASSESSES CURRENT PROGRESS OF STUDY AS STILL ON TRACK.SALES OF WOXHEAL(R) IN INDIA HAVE INCREASED SLIGHTLY TO OVER 10,000 USE CASES COMPARED TO Q4 OF 2020.CONFIDENT THAT NUMBER OF TREATMENTS CAN INCREASE NOTICEABLY IN SECOND HALF OF 2021 AND THAT ROLL-OUT OF PRODUCT WILL BE ACCELERATED AS ORIGINALLY PLANNED.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary